•  

Posts Tagged: Baxter International Inc.

MaRS Innovation Industry Access Program (MI-IAP) accepting applications until April 10

Researchers working in orphan indications, drug delivery devices, big data and other key areas invited to submit a brief Statement of Interest The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and Merck. The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs. First run in November 2013, the MI-IAP allows researchers to easily ... Read more

Baxter and MaRS Innovation Form Strategic Partnership

Partnership to invest up to $1M in promising Canadian healthcare discoveries TORONTO, Ontario, October 4, 2012—Baxter International Inc. and MaRS Innovation, a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in therapeutics and drug discovery technologies. Information about Baxter and MaRS Innovation's partnership is also available in French. The partnership’s shared vision for delivering novel, transformative therapeutic technologies will benefit Canadians and others around the world. Baxter and MaRS Innovation will ... Read more